drugset / Trial / NCT06025552
Study of TU7710 in Warfarin Anti-coagulated Healthy Male Subjects
RandomizedSequentialDouble-blindTreatment
Summary
This is a Phase 1a, double-blind, randomized, placebo- controlled, SAD study to assess safety, tolerability, PK, and PD of TU7710 in warfarin treated healthy male participants.
Timeline
- Start
- 2023-08-02
- Primary completion
- 2024-08-21
- Completion
- 2024-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TU7710 | Unknown | 100 ug/kg | Intravenous |
| Subject | TU7710 | Unknown | 200 ug/kg | Intravenous |
| Subject | TU7710 | Unknown | 400 ug/kg | Intravenous |
| Subject | TU7710 | Unknown | 800 ug/kg | Intravenous |